Research and Markets: Brain Ischemia - Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia) has announced the addition of the "Brain Ischemia - Pipeline Review, H2 2015" report to their offering.

The report, Brain Ischemia - Pipeline Review, H2 2015, provides an overview of the Brain Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Brain Ischemia and special features on late-stage and discontinued projects.

Key Topics Covered:

  • Snapshot of the global therapeutic landscape of Brain Ischemia
  • Key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • Key players involved in the therapeutics development for Brain Ischemia and enlists all their major and minor projects
  • All dormant and discontinued pipeline projects
  • Brain Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • Detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Benefits of this Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Ischemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • CohBar Inc.
  • Immune Pharmaceuticals Inc.
  • Lixte Biotechnology Holdings, Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Prolong Pharmaceuticals
  • Spectrum Pharmaceuticals, Inc.
  • Sylentis S.A.
  • The International Biotechnology Center (IBC) Generium
  • Vect-Horus S.A.S

For more information visit http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia

Contacts:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.